• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA scraps adcomm for Applied's rare disease drug ahead of November decision

cafead

Administrator
Staff member
  • cafead   Sep 18, 2024 at 02:12: PM
via After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided that a planned advisory committee meeting won’t be required.

article source